<DOC>
	<DOCNO>NCT02226341</DOCNO>
	<brief_summary>Systemic Lupus Erythematosus ( SLE ) disease immune system attack healthy cell tissue , cause inflammation damage organs body . About 50 % SLE patient experience inflammation kidney . The purpose study determine effectiveness safety two dosing arm ACTHar gel treat proliferative Lupus Nephritis ( LN ) . This study hypothesize dose arm ACTHar safe effective treat proliferative LN ( Class III IV ) .</brief_summary>
	<brief_title>ACTHar Treatment Lupus Nephritis</brief_title>
	<detailed_description>Systemic Lupus Erythematosus ( SLE ) autoimmune disease unknown etiology mainly affect female childbearing age . The disease characterize immune activation development autoantibody . About 50 % SLE patient experience inflammation kidney . Lupus Nephritis ( LN ) major cause morbidity mortality patient SLE . Mycophenolate Mofetil ( MMF ) , accompany Prednisone , consider current standard care LN . However , long-term use Prednisone many serious side effect . ACTHar Gel FDA approve drug comprise active substance call adrenocorticotropic hormone ( ACTH ) . ACTH belongs anti-inflammatory group call melanocortins carry effect bind five different melanocortin receptor ( MCRs ) . Specifically , ACTH bind melanocortin 2 receptor subtype ( MC2R ) adrenal cortex stimulate production cortisol reduce inflammation kidney . In addition bind melanocortin 1-5 receptor subtype ( MC1-5R ) act directly kidney tissue , ACTH may bind MCRs various cell type , immune cell , activate process protect kidney . This study evaluate effective dose ACTHar gel proliferative LN ( Class III IV ) give MMF , standard care LN therapy . The intent study determine effectiveness safety ACTHar gel attempt change clinical care requirement regard steroid use treat LN .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Diagnosis Systemic Lupus Erythematosus ( SLE ) American College Rheumatology ( ACR ) /SLICC criterion 2 . Age â‰¥ 16 year 3 . Active lupus nephritis define : a. Kidney biopsy documentation International Society Nephrology/Renal Pathology Society ( ISN/RPS ) Class III Class IV proliferative nephritis ( include Class V occur combination Class III IV ) within 12 month urine protein/creatinine ratio &gt; 1 time entry study 4 . Ability provide inform consent 1 . Moderately severe anemia ( Hgb &lt; 8 mg/dL ) 2 . Neutropenia ( &lt; 1,000/mm3 ) 3 . Thrombocytopenia ( platelet &lt; 50,000/mm3 ) 4 . Positive purified protein derivative ( PPD ) test confirm positive Quantiferon TB gold . 5 . Pulmonary fibrotic change chest radiograph consistent prior heal tuberculosis 6 . Active infection opinion investigator increase risk subject . 7 . Known human immunodeficiency virus ( HIV ) hepatitis B C 8 . Endstage renal disease ( estimate GFR clearance &lt; 20 mL/min/1.73 m2 ) 9 . History cancer , except carcinoma situ treat basal squamous cell carcinomas 10 . Pregnancy 11 . Lactation 12 . Unwillingness use medically acceptable form birth control ( include limit diaphragm , intrauterine device , progesterone implant injection , oral contraceptive , doublebarrier method , condom ) 13 . Previous failure respond MMF 14 . Use rituximab within past year 15 . Use experimental therapeutic agent within past 60 day 16 . Greater equal 5 time upper limit normal liver function test ( aspartate aminotransferase [ AST ] , alanine aminotransferase [ ALT ] , alkaline phosphatase ) 17 . Severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological disease ( , investigator 's opinion , concomitant medical condition place participant risk participate study ) exception disease condition relate active SLE 18 . Current substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Lupus Nephritis</keyword>
	<keyword>ACTHar</keyword>
	<keyword>Columbia</keyword>
	<keyword>Rheumatology</keyword>
	<keyword>CUMC</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>SLE</keyword>
	<keyword>Proliferative Lupus Nephritis</keyword>
</DOC>